Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies have demonstrated that long non-coding RNAs (lncRNAs) were present in the blood of cancer patients and have shown great potential as powerful and non-invasive tumor markers. However, little is known about the value of lncRNAs in the diagnosis of esophageal squamous cell carcinoma (ESCC). We hypothesized that ESCC-related lncRNAs might be released into the circulation during tumor initiation and could be utilized to detect and monitor ESCC. METHODS: Ten lncRNAs (HOTAIR, AFAP1-AS1, POU3F3, HNF1A-AS1, 91H, PlncRNA1, SPRY4-IT1, ENST00000435885.1, XLOC_013104 and ENST00000547963.1) which previously found to be differently expressed in esophageal cancer were selected as candidate targets for subsequent circulating lncRNA assay. A four-stage exploratory study was conducted to test the hypothesis: (1) optimization of detected method to accurately and reproducibly measure ESCC-related lncRNAs in plasma and serum; (2) evaluation of the stability of circulating lncRNAs in human plasma or serum; (3) exploration the origin of ESCC-related lncRNAs in vitro and in vivo; (4) evaluation the diagnostic power of circulating lncRNAs for ESCC. RESULTS: ESCC-related lncRNAs were detectable and stable in plasma of cancer patients, and derived largely from ESCC tumor cells. Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls. By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842; p < 0.001; sensitivity, 72.8%; specificity, 89.4%). Moreover, use of POU3F3 and SCCA in combination could provide a more effective diagnosis performance (AUC, 0.926, p < 0.001, sensitivity, 85.7%; specificity, 81.4%). Most importantly, this combination was effective to detect ESCC at an early stage (80.8%). CONCLUSIONS: Plasma POU3F3 could serve as a potential biomarker for diagnosis of ESCC, and the combination of POU3F3 and SCCA was more efficient for ESCC detection, in particular for early tumor screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun, G., Stentrup, M., Groß, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2850 · Cited by 1,415
Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879 · cited 2×
“circulating miRNAs and that perturbations in blood cell counts and hemolysis could alter plasma miRNAs levels by up to 50-fold [25].”
BackgroundStability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma
Tsui, N. B., Ng, E. K., & Lo, Y. D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1647 · Cited by 627
Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure
Kumarswamy, R., Bauters, C., Volkmann, I., Maury, F., Fetisch, J., Holzmann, A., Lemesle, G., de Groote, P., Pinet, F., & Thum, T. (2014) · Circulation Research · doi:10.1161/circresaha.114.303915 · Cited by 625
The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine
Qi, P., & Du, X. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.160 · Cited by 506
TNM Classification of Malignant Tumours, 7th Edition
Wittekind, C., Gospodarowicz, M. K., & Sobin, L. H. (2009) · Cited by 485
Li, J., Chen, Z., Tian, L., Zhou, C., He, M. Y., Gao, Y., Wang, S., Zhou, F., Shi, S., Feng, X., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305806 · Cited by 438
Self-citationLncRNA loc285194 is a p53-regulated tumor suppressor
Liu, Q., Huang, J., Zhou, N., Zhang, Z., Zhang, A., Lu, Z., Wu, F., & Mo, Y.-Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt182 · Cited by 384
Yuan, S.-X., Yang, F., Yang, Y., Tao, Q.-F., Zhang, J., Huang, G., Yang, Y., Wang, R.-Y., Yang, S., Huo, X.-S., et al. (2012) · Hepatology · doi:10.1002/hep.25895 · Cited by 374
Ren, S., Wang, F., Shen, J., Sun, Y., Xu, W., Lu, J., Wei, M., Xu, C., Wu, C., Zhang, Z., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.026 · Cited by 312
Self-citationCombination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer
Liu, J., Gao, J., Du, Y., Li, Z., Ren, Y., Gu, J., Wang, X., Gong, Y., Wang, W., & Kong, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.26422 · Cited by 309
Self-citationTakeshita, N., Hoshino, I., Mori, M., Akutsu, Y., Hanari, N., Yoneyama, Y., Ikeda, N., Isozaki, Y., Maruyama, T., Akanuma, N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.8 · Cited by 262
Ng, E. K., Tsui, N. B., Lam, N. Y., Chiu, R. W., Yu, S. C., Wong, S. C., Lo, E. S., Rainer, T. H., Johnson, P. J., & Lo, Y. D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1212 · Cited by 260
Serum microRNAs as powerful cancer biomarkers
Wittmann, J., & Jäck, H.-M. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.002 · Cited by 257
Wu, W., Bhagat, T. D., Yang, X., Song, J. H., Cheng, Y., Agarwal, R., Abraham, J. M., Ibrahim, S., Bartenstein, M., Hussain, Z., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.019 · Cited by 234
Jacob, F., Guertler, R., Naim, S., Nixdorf, S., Fedier, A., Hacker, N. F., & Heinzelmann-Schwarz, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059180 · Cited by 217
Yang, X., Song, J. H., Cheng, Y., Wu, W., Bhagat, T., Yu, Y., Abraham, J. M., Ibrahim, S., Ravich, W., Roland, B. C., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305266 · Cited by 209
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations
Redis, R. S., Sieuwerts, A. M., Look, M. P., Tudoran, O., Ivan, C., Spizzo, R., Zhang, X., de Weerd, V., Shimizu, M., Ling, H., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1292 · Cited by 176
Li, W., Zheng, J., Deng, J., You, Y., Wu, H., Li, N., Lu, J., & Zhou, Y. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.002 · Cited by 168
Li, X., Wu, Z., Mei, Q., Li, X., Guo, M., Fu, X., & Han, W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.548 · Cited by 164
Perspectives of Long Non-Coding RNAs in Cancer Diagnostics
Reis, E. M., & Verjovski-Almeida, S. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00032 · Cited by 164
Kosugi, S., Nishimaki, T., Kanda, T., Nakagawa, S., Ohashi, M., & Hatakeyama, K. (2004) · World Journal of Surgery · doi:10.1007/s00268-004-6865-y · Cited by 132
Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer
Zanutto, S., Pizzamiglio, S., Ghilotti, M., Bertan, C., Ravagnani, F., Perrone, F., Leo, E., Pilotti, S., Verderio, P., Gariboldi, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.819 · Cited by 129
Hirajima, S., Komatsu, S., Ichikawa, D., Takeshita, H., Konishi, H., Shiozaki, A., Morimura, R., Tsujiura, M., Nagata, H., Kawaguchi, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.148 · Cited by 121
Lardizábal, M. N., Nocito, A. L., Daniele, S. M., Ornella, L., Palatnik, J. F., & Veggi, L. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036323 · Cited by 116
Circulating miRNAs as New Blood-Based Biomarkers for Solid Cancers
Rédová, M., Šáňa, J., & Slabý, O. (2013) · Future Oncology · doi:10.2217/fon.12.192 · Cited by 112
A review of the current understanding and clinical utility of miRNAs in esophageal cancer
Sakai, N. S., Samia‐Aly, E., Barbera, M., & Fitzgerald, R. C. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.005 · Cited by 109
Xie, H., Wu, Q., Zhu, B., Chen, F., Ji, L., Li, S., Wang, C., Tong, Y., Tuo, L., Wu, M., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2013-y · Cited by 107
Self-citationWang, C., Wu, Q., Li, S., Chen, F., Tuo, L., Xie, H., Tong, Y., Ji, L., Zhou, G., Cao, G., et al. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2956-7 · Cited by 86
Self-citationSecretory miRNAs as novel cancer biomarkers
Zhang, J., Zhao, H., Gao, Y., & Zhang, W. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.001 · Cited by 85
CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma
Yamamoto, K., Oka, M., Hayashi, H., Tangoku, A., Gondo, T., & Suzuki, T. (1997) · Cancer · Cited by 75
Gao, T., He, B., Pan, Y., Xu, Y., Li, R., Deng, Q., Sun, H., & Wang, S. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22106 · Cited by 57
Łukaszewicz‐Zając, M., Mroczko, B., Kozłowski, M., Nikliński, J., Laudanski, J., & Szmitkowski, M. (2011) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2011.01242.x · Cited by 48
Sauer, E., Babion, I., Madea, B., & Courts, C. (2014) · Forensic Science International Genetics · doi:10.1016/j.fsigen.2014.08.005 · Cited by 45
Could circulating miRNAs contribute to cancer therapy?
Chen, G., Wang, J., & Cui, Q. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.10.006 · Cited by 43
Cited by
Long Noncoding RNA and Cancer: A New Paradigm
Bhan, A., Soleimani, M., & Mandal, S. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2634 · Cited by 2,861
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
Long Noncoding RNAs as Biomarkers in Cancer
Bolha, L., Ravnik-Glavač, M., & Glavač, D. (2017) · Disease Markers · doi:10.1155/2017/7243968 · Cited by 365
Zhang, E., Han, L., Yin, D., He, X., Hong, L., Si, X., Qiu, M., Xu, T., De, W., Xu, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1247 · Cited by 341
Zhou, X., Yin, C., Dang, Y., Ye, F., & Zhang, G. (2015) · Scientific Reports · doi:10.1038/srep11516 · Cited by 334
Self-citation
Metadata
- Authors
- Tong, Y.-S., Wang, X.-W., Zhou, X.-L., Liu, Z.-H., Yang, T.-X., Shi, W.-H., Xie, H.-W., Lv, J., Wu, Q.-Q., & Cao, X.-F.
- Venue
- Molecular Cancer
- Published
- 2015
- Volume
- 14
- Issue
- 1
- Pages
- 3
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2111119573
- Cited by
- 317
- References
- 39
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.